Minneapolis, MN – A new medication called atogepant has shown promise in offering rapid relief to those suffering from migraines. As part of three clinical trials, researchers found that patients who took the medication experienced significant improvements in reducing the frequency and severity of their migraines within the first four weeks of treatment.
Atogepant belongs to the class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is designed to block the action of a protein called CGRP, which is responsible for causing blood vessels to dilate and promoting inflammation in the brain. By blocking these receptors, atogepant can help prevent the progression of migraine attacks.
The researchers conducted three phase three trials, involving over 1,250 patients from multiple countries. The trials found that patients taking atogepant experienced 12% to 51% fewer migraines compared to those taking a placebo on the first day, with improvements sustained throughout the 12-week treatment period.
The study’s lead author, Dr. Richard B. Lipton, noted that traditional preventive medications often require weeks or months of daily use before patients experience meaningful benefits. “With many current drugs to prevent migraine, it takes time to find the right dosage for the individual, and it can take weeks or even months for it to be most effective,” he said. “Developing a drug that works both effectively and quickly is critical.”
In total, 4,500 doses of atogepant were administered to patients, who were required to keep electronic diaries to track their migraines, symptoms, and ability to function. The results showed that atogepant significantly reduced the number of migraine days experienced by patients, with the most pronounced benefits seen in patients with chronic migraines.
The study’s outcomes and the rapid response of atogepant may revolutionize the way migraines are treated, as they offer a more powerful and swift action compared to traditional medications. With side effects reported to be mild and similar to those of a placebo, atogepant may provide an effective and well-tolerated option for those suffering from migraines.